ANI Pharmaceuticals 2026: Revenue $266.04M, EPS $1.05— 10-Q Summary
ANI Pharmaceuticals reported second-quarter 2026 net revenues of $266.04M, up from $211.37M, and diluted EPS of $1.05 versus $0.36. Net income rose to $24.71M from $8.55M. Growth was attributed to Rare Disease (Cortrophin Gel) and generics volume. The company also noted a shift in U.S. ophthalmology promotion from YUTIQ to ILUVIEN.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term earnings power based on reported revenue, EPS, and net income growth, plus product-specific drivers (Cortrophin Gel volume gains and ILUVIEN label expansion).
Market read
A straightforward quarterly earnings update with product-level drivers, useful for positioning around specialty pharma demand and rare-disease momentum.
What to watch
The summary does not include guidance, cash flow, or inventory/receivables changes, which are often key for trading after a 10-Q.
Background
The piece is a brief summary of ANI Pharmaceuticals’ Q2 2026 10-Q filed Aug. 7, 2026.
Ticker impact
ANI Pharmaceuticals reported Q2 2026 revenue of $266.04M and diluted EPS of $1.05, with net income rising to $24.71M.
Likely near-term positive bias as traders price in improving profitability and volume momentum.
The article provides concrete quarterly financials and specific business drivers (Cortrophin Gel volume gains, generics volume, ILUVIEN label expansion), which can influence expectations for subsequent quarters.
Market effects
Supports the rare-disease and ophthalmology product-cycle narrative (YUTIQ to ILUVIEN shift) for specialty pharma investors.
No explicit regional demand or regulatory changes mentioned.
No direct global expansion or international regulatory actions disclosed.
Counterpoint
Volume gains may not translate into durable margins if promotional shifts or manufacturing ramp costs rise later.
Key entities
- companyANI Pharmaceuticals
Reported Q2 2026 net revenues of $266.04M, diluted EPS of $1.05, and net income of $24.71M, citing rare disease and generics volume.
- productCortrophin Gel
Cited as driving rare-disease volume and market-share gains.
- productILUVIEN
Label expanded to include chronic NIU-PS; YUTIQ had no sales in 2026 quarters per the summary.
